Welcome to our dedicated page for MESOBLAST SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESOBLAST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESOBLAST's regulatory disclosures and financial reporting.
Mesoblast Limited submitted a Form 6-K to provide U.S. investors with materials it filed with the Australian Securities Exchange. The report states that on November 25, 2025, the company lodged the Chair’s Annual General Meeting address and the CEO’s presentation to the Annual General Meeting, which are included as Exhibits 99.1 and 99.2. It also includes a press release dated the same day as Exhibit 99.3. These documents are incorporated by reference, making the Australian-market communications available to investors following Mesoblast’s U.S. listing.
Mesoblast Limited, an Australia-incorporated company, submitted a Form 6-K as a foreign private issuer. The report forwards a news release announcement that Mesoblast filed with the Australian Securities Exchange on November 5, 2025, attaching it as Exhibit 99.1 and incorporating it by reference.
The filing is signed on behalf of Mesoblast Limited by Company Secretary Paul Hughes, dated November 5, 2025.
Mesoblast Limited furnished a Form 6-K to provide investors with Australian Securities Exchange materials. The filing attaches two ASX documents dated October 28, 2025: an Appendix 3Y change of director’s interest notice and an Appendix 3G notification of issue, conversion or payment up of unquoted equity securities, incorporated by reference as Exhibits 99.1 and 99.2.
This update is administrative, making the ASX disclosures available to U.S. investors under the Exchange Act.
Mesoblast Limited furnished a Form 6-K detailing the availability of key shareholder materials filed with the Australian Securities Exchange. The submission includes the company’s Annual Report to Shareholders, a Notice of Annual General Meeting, and an Appendix 4G with Corporate Governance Statement, each attached as Exhibits 99.1, 99.2, and 99.3 and incorporated by reference.
Mesoblast reports as a foreign private issuer and files annual reports under Form 20-F. The filing identifies Australia as the jurisdiction of incorporation and lists the principal office at Level 38, 55 Collins Street, Melbourne 3000, Australia. The report was signed by Company Secretary Niva Sivakumar on October 28, 2025.
Mesoblast Limited furnished a Form 6-K to provide investors with its Australian Securities Exchange Appendix 4C quarterly report for the quarter ended September 30, 2025. The Appendix 4C is attached as Exhibit 99.1 and incorporated by reference. The filing is an administrative submission linking U.S. investors to the company’s ASX quarterly cash flow and activities report.
Mesoblast Limited furnished a Form 6-K noting that, on October 15, 2025, it filed several announcements with the Australian Securities Exchange. The report attaches and incorporates by reference four ASX documents: Appendix 3G (notification of issue, conversion or payment up of unquoted equity securities), Appendix 3H (notification of cessation of securities), Appendix 3Y (change of director’s interest notice), and Appendix 2A (application for quotation of securities).
The exhibits are labeled 99.1 through 99.4 and the report is signed by Company Secretary Niva Sivakumar.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for October 2025. The report states that on October 7, 2025, the company filed a news release announcement with the Australian Securities Exchange, which is attached as Exhibit 99.1 and incorporated by reference. The filing itself mainly serves to furnish this press release to U.S. investors.